Fewer than one in 10 patients who could benefit from obesity jabs such as Wegovy can access them, warns the WHO as it publishes its inaugural advice on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for increased and just access to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 unless action is taken.
"Our new guidelines affirms that obesity is a long-term condition that can be managed with thorough and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are major barriers to widespread access to the treatments that can aid individuals in losing significant body mass, explains the organization.
Skinny Jab Supply Crisis
Despite the present most optimistic scenario, the production of these medications might only reach around 100 million people – fewer than 10% of the global need, per the WHO.
The guideline encourages nations and manufacturers to increase availability, via approaches including voluntary licensing.
The intellectual property rights on a key compound – the primary ingredient of a leading brand – is set to lapse in a number of nations in 2026.
How Obesity Jabs Function
GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so people consume fewer calories.
Patients usually start to lose weight in the initial weeks of beginning the regular doses.
Research suggests people may regain a significant portion within a year of discontinuing the treatment, when their typical hunger resume.
To be carrying excess weight increases your likelihood for developing diseases, including diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in all nations and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
